Loading…
← CockpitCompetitor Analysis › VIYASH.NS Viyash Scientific LimitedOpen in the cockpit ↗

Viyash Scientific LimitedVIYASH.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Contract manufacturer of pharmaceutical formulations, producing dosage forms for other pharma companies in India.

≈ A pharma contract formulation manufacturerMomentum neutral 54
Mkt cap
$1.11B
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$6.64M
20-day average traded
Fwd P/E
32.2×
forward earnings
ROIC−WACC
-9.3 pp
WACC 19.1%
Hurdle
+16 pp
Req g minus delivered
Next earnings
88 days
14 Feb 2027
Close · INR₹235.61
1D-0.8%
1W-7.5%
1M+6.6%
3M-7.6%
6M+3.0%
YTD+13.0%
1Y-1.1%
ATR %4.4%
Beta1.16
52w lowhigh20.9% off high

What Viyash Scientific does

Contract manufacturer of pharmaceutical formulations, producing dosage forms for other pharma companies in India.

In one line: A pharma contract formulation manufacturer.

Products and services

  • Contract formulation manufacturing
  • Dosage form development

Customers

  • Domestic and export pharma companies (contract cli

Where it sits in the supply chain

  • Formulation manufacturing (CDMO)
  • Sale to branded pharma companies

What could go right

  • Pharma contract manufacturing outsourcing growth

What could go wrong

  • Customer concentration
  • Thin contract-manufacturing margins

Moat: none (process know-how). Contract manufacturing scale, but limited pricing power versus branded pharma customers.

Headquarters: India · Employees: 4,131

Named competitors

Viyash Scientific at a glance

Size Viyash Scientific (VIYASH.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.11B, the 568th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹235.61 on 18 Nov 2026.

Performance Over six months the shares gained 3.0%, against -11.7% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 123.9% over the last twelve months (peer median -1.5%); the operating margin is 13.1% (peer median 4.5%).

Valuation It trades at 32.2× forward earnings against a peer median of 20.2× (3rd most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 9.3 points below its cost of capital (19.1% WACC).

Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026VIYASH.NS 94Peer median 90
Six months, rebased to 100: Viyash Scientific against the median of its 20 peers (local-currency closes).

Viyash Scientific financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹37.1B₹34.2B₹30.1B₹13.7B₹14.2B
Revenue growth—+14%+120%-4%—
Gross profit₹11.6B₹7.79B₹4.80B₹1.85B₹1.60B
EBITDA₹7.11B₹6.57B₹3.94B₹649M₹460M
Net income₹2.33B₹1.77B₹232M-₹359M-₹1.21B
Free cash flown/a₹1.29B₹1.66B-₹449M-₹1.05B
Capital expendituren/a₹1.35B₹1.08B₹308M₹862M
Total debt₹5.84B₹4.90B₹6.54B₹4.88B₹4.44B

Quarterly statements and history in the cockpit →

Viyash Scientific competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%237690006280300119VETOCMHCPYCMEDCL4547600812OMER0009896855NKTR1952688443BLUEJET688321600789VIYASH.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Viyash Scientific is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×200×400×237690006280300119CMHC0009891952BLUEJET688321VIYASH.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Viyash Scientific is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%237690300119VETO002550600812000989BLUEJET600789VIYASH.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Viyash Scientific is the large dot.

Viyash Scientific competitors and peer comparison

Head to head with its named competitors (VIYASH.NS vs PPLPHARMA.NS vs COHANCE.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Viyash Scientific VIYASH.NS$1.11B+3%+124%13%32.2×36.3%
Piramal Pharma PPLPHARMA.NS$3.40B+38%+9%3%150.8×n/a
Cohance Lifesciences COHANCE.NS$1.87B+7%+14%2%96.3×n/a

How Viyash Scientific compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Viyash Scientific against its 20 peers (data as of 18 Nov 2026)
MeasureVIYASH.NSPeer medianRank in peer set
1-month return+6.6%-2.3%4th highest of 21
6-month return+3.0%-11.7%7th highest of 20
Distance from 52-week high-20.9%-33.1%6th highest of 21
Revenue growth (TTM)+123.9%-1.5%3rd highest of 18
Operating margin13.1%4.5%6th highest of 19
Forward P/E32.2×20.2×3rd most expensive of 13
Growth the price implies (Req g, 7 yrs)36.3%2.9%2nd most demanding of 9
Growth delivered (Del g)+20.4%+5.4%2nd highest of 9
Hurdle (Req g minus delivered)+16.0 pp+0.3 pp2nd most demanding of 9
ROIC minus cost of capital-9.3 pp-3.0 pp8th lowest of 19
EV / EBITDA15.1×13.2×2nd most expensive of 6
Net debt / EBITDA0.1×-1.7×2nd most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%32.2×36.3%+20.4%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%27.8×4.2%+21.7%
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%n/an/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%

Questions

Who are Viyash Scientific's main competitors?
Named competitors: Piramal Pharma (PPLPHARMA.NS), Cohance Lifesciences (COHANCE.NS). The cockpit's measured peer set (industry) also includes ST Pharm (237690.KS), Symbiotec Pharmalab (SYMBIOTEC.NS), GC Biopharma (006280.KS), Tianjin Ringpu Bio-technology (300119.SZ), Vetoquinol (VETO.PA), Cosmo (CMHC.SW).
Is Viyash Scientific expensive compared with its peers?
On forward p/e it trades at 32.2× against a peer median of 20.2×, 3rd most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Viyash Scientific stock performed?
Over six months to 18 Nov 2026 the shares returned +3.0% against -11.7% for the median peer; over one year -1.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.